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It was 1997 when I decided to be an Oncologist. 
At that time I was finishing my 2-year training in Clínica 
Médica at Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo - HCFMUSP. Considering 
all patients admitted to the wards, up to 30% of them had 
been diagnosed with a cancer, considering both solid and 
hematologic neoplasms. The Oncology division of InRad 
(Instituto de Radiologia) had only six attending physicians 
in six consulting rooms, shared with Radiotherapy 
colleagues.
Residency program was started in 1999 with two 
Oncology fellows in InRad. Nowadays at ICESP (Instituto 
do Câncer do Estado de São Paulo) we have 14 fellows 
every year, and our Program of training in Oncology has 
been ranked among the top 5 best in the annual evaluation 
of Oncology trainees conducted by the American 
Society of Clinical Oncology (ASCO) in more than 200 
institutions around the world. As the largest Cancer center 
in South America, in 2014 more than 250,000 outpatient 
consultations were done at ICESP, and more than 9,000 
surgeries.
It is important to mention that research is among 
the most important activities conducted in our Hospital. 
ICESP researchers are involved in many research projects 
from basic science to clinical research, and these results 
has been presented in international forums and published 
in high-quality peer-reviewed journals.
One of my areas of interest is Thoracic Oncology, 
and in the last 15 years I could face a tremendous change 
in how to better diagnose, treat and prevent lung cancer. 
Important progress did occur, and some landmarks must be 
mentioned: (1) incorporation of cisplatin-based adjuvant 
chemotherapy; (2) better classification of lung cancer in 
terms of histologic subtypes and more adequate staging; 
(3) molecular-based selection of systemic therapies; (4) 
the development of immunotherapy protocols to treat lung 
cancer, among others.
The intensive participation of our patients in the 
clinical research program at ICESP allows them to be 
treated with new treatment options, most of them not 
available for the cancer patients under SUS coverage. To 
be part of this initiative is a privilege!
